D. Ciprofloxacin in nentropenia
Downloaded from http://jac.oxfordjournals.org/ at University of Manitoba on June 6, 2015
Journal of Antimicrobial Chemotherapy (1990) 26, Suppl. F, 89-99
Randomized multicentre study of ciprofloxacin and azlodllin versus gentamicin and azlodllin in the treatment of febrile neutropenic patients J. N. Phflpott-Howard, K. F. Barker*, J. J. Wade, R. S. Kaczmarskf, J. C. Smedley" and G. J. Mufti' Departments of Medical Microbiology and 'Haematological Medicine, Kings College School of Medicine & Dentistry, Bessemer Road, London SE5 9RX, UK
Introduction Bacterial infection continues to be a major cause of morbidity and mortality in neutropenic patients; the risk of life-threatening infection increases severalfold as the peripheral neutrophil count falls below 0-5 x 10*/l (Schimpff, 1977). Prompt antimicrobial treatment of suspected infection has contributed significantly to the improved outcome in patients with malignant disease by allowing the use of more intensive cytotoxic regimens. For such patients the combination of an aminoglycoside and a /?Participating investigators (UK): Dr J. Whittaker, University Hospital of Wales, Cardiff; Dr I. Franklin, Queen Elizabeth Hospital, Birmingham; Dr R. Hyde, Dr D. Chisholm & Dr A. Pallett, Southampton General Hospital, Southampton; Dr M. Mackk, Western General Hospital, Edinburgh; Dr Al-Ismail & Dr A. Beddall, Morroton Hospital and Singleton Hospital, Swansea; Dr J. McCaHum, Royal Victoria Hospital, Kircaldy; Dr G. J. Mufti. Kine's College Hospital. London. •Present address; The Public Health Laboratory, St George's Hospital, Tooting, London SW17 0QT, UK. 89 0305-7453/90/26FO89+ 11 $02.00/0
© 1990 The British Society for Antimicrobial Chemotherapy
Downloaded from http://jac.oxfordjournals.org/ at University of Manitoba on June 6, 2015
In a randomized multicentre study ciprofloxacin combined with azlocillin was compared with gentamicin and azlocillin for the treatment of febrile episodes in neutropenic patients. In 147 evaluable episodes in 108 patients, 80 patients received ciprofloxacin/azlocillin and 67 received gentamicin/azlocillin. The two treatment groups were comparable in terms of age, underlying diagnosis, and duration of neutropenia. Microbiologically documented infections were the cause of fever in 34 (42-5%) and 29 (433%) episodes in the ciprofloxacin/azlocillin and gentamicin/ azlocillin groups respectively. At the end of therapy, 46 patients (57-5%) receiving dprofloxacin/azlociliin showed complete resolution compared with 30 (44-7%) for the gentamicin/azlocillin group (P
Downloaded from http://jac.oxfordjournals.org/ at University of Manitoba on June 6, 2015
Journal of Antimicrobial Chemotherapy (1990) 26, Suppl. F, 89-99
Randomized multicentre study of ciprofloxacin and azlodllin versus gentamicin and azlodllin in the treatment of febrile neutropenic patients J. N. Phflpott-Howard, K. F. Barker*, J. J. Wade, R. S. Kaczmarskf, J. C. Smedley" and G. J. Mufti' Departments of Medical Microbiology and 'Haematological Medicine, Kings College School of Medicine & Dentistry, Bessemer Road, London SE5 9RX, UK
Introduction Bacterial infection continues to be a major cause of morbidity and mortality in neutropenic patients; the risk of life-threatening infection increases severalfold as the peripheral neutrophil count falls below 0-5 x 10*/l (Schimpff, 1977). Prompt antimicrobial treatment of suspected infection has contributed significantly to the improved outcome in patients with malignant disease by allowing the use of more intensive cytotoxic regimens. For such patients the combination of an aminoglycoside and a /?Participating investigators (UK): Dr J. Whittaker, University Hospital of Wales, Cardiff; Dr I. Franklin, Queen Elizabeth Hospital, Birmingham; Dr R. Hyde, Dr D. Chisholm & Dr A. Pallett, Southampton General Hospital, Southampton; Dr M. Mackk, Western General Hospital, Edinburgh; Dr Al-Ismail & Dr A. Beddall, Morroton Hospital and Singleton Hospital, Swansea; Dr J. McCaHum, Royal Victoria Hospital, Kircaldy; Dr G. J. Mufti. Kine's College Hospital. London. •Present address; The Public Health Laboratory, St George's Hospital, Tooting, London SW17 0QT, UK. 89 0305-7453/90/26FO89+ 11 $02.00/0
© 1990 The British Society for Antimicrobial Chemotherapy
Downloaded from http://jac.oxfordjournals.org/ at University of Manitoba on June 6, 2015
In a randomized multicentre study ciprofloxacin combined with azlocillin was compared with gentamicin and azlocillin for the treatment of febrile episodes in neutropenic patients. In 147 evaluable episodes in 108 patients, 80 patients received ciprofloxacin/azlocillin and 67 received gentamicin/azlocillin. The two treatment groups were comparable in terms of age, underlying diagnosis, and duration of neutropenia. Microbiologically documented infections were the cause of fever in 34 (42-5%) and 29 (433%) episodes in the ciprofloxacin/azlocillin and gentamicin/ azlocillin groups respectively. At the end of therapy, 46 patients (57-5%) receiving dprofloxacin/azlociliin showed complete resolution compared with 30 (44-7%) for the gentamicin/azlocillin group (P
